The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.<\/p>\n
1320 ET \u2013 MBX Biosciences is off 5.5% following results of a Phase 2 trial of its canvuparatide treatment for hypoparathyroidism. Mizuho says the drug achieved a 57% composite responder rate, a metric for treatment success, at 52 weeks, which is comparable to its competitor Yorvipath\u2019s 64%. That said, the analysts believe some investors might argue that Yorvipath\u2019s real benchmark rate is 80% under a more relaxed standard tied to patient use. But the analysts are still upbeat on the results and canvuparatide\u2019s once-weekly dosing schedule, which allows for 86% fewer injections and \u201ccontinue to support canvuparatide\u2019s commercial potential,\u201d they say. (dean.seal@wsj.com<\/a>)<\/p>\n Copyright \u00a92026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8<\/p>\n","protected":false},"excerpt":{"rendered":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET,…\n","protected":false},"author":2,"featured_media":481400,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[89162,89156,30906,241996,102249,89159,44547,47880,89160,19202,3717,134,527,101297,47884,6422,241997,1428,111,101295,139,69,1674,18154,47881,42775,1321,19201,101230],"class_list":["post-481399","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-analysts-comments","tag-analysts-comments-recommendations","tag-biopharmaceuticals","tag-biotechnology-services","tag-ce-exclusion-filter","tag-content-types","tag-corporate","tag-corporate-industrial-news","tag-factiva-filters","tag-gcapi","tag-general-news","tag-health","tag-healthcare","tag-healthcare-life-sciences","tag-industrial-news","tag-life-sciences","tag-linkendrnrealtime-linkedarticle-dnco20260612006867","tag-manufacturing","tag-new-zealand","tag-newsplus","tag-newzealand","tag-nz","tag-pharmaceuticals","tag-political","tag-political-general-news","tag-recommendations","tag-services","tag-synd","tag-wsj-pro-wsj-com"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/481399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=481399"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/481399\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/481400"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=481399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=481399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=481399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}